{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:40:14Z","timestamp":1781080814224,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA167540"],"award-info":[{"award-number":["K12CA167540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005227","name":"Centers for Medicare and Medicaid Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013347","name":"Institute of Translational Health Sciences, University of Washington","doi-asserted-by":"publisher","award":["UL1 TR000448"],"award-info":[{"award-number":["UL1 TR000448"]}],"id":[{"id":"10.13039\/100013347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["KM1CA156708"],"award-info":[{"award-number":["KM1CA156708"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.clml.2018.01.005","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:57:07Z","timestamp":1517482627000},"page":"219-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies"],"prefix":"10.1016","volume":"18","author":[{"given":"Bita","family":"Fakhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.01.005_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.01.005_bib2","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.005_bib3","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbmt.2015.03.005","article-title":"Re: disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Fiala","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2018.01.005_bib4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.01.005_bib5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1996.14.3.974","article-title":"Evaluation of race as a prognostic factor in multiple myeloma: an ancillary of Southwest Oncology Group Study 8229","volume":"14","author":"Modiano","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib7","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bmt.1705392","article-title":"Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma","volume":"37","author":"Saraf","year":"2006","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2018.01.005_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.21139","article-title":"The impact of race on outcomes of autologous transplantation in patients with multiple myeloma","volume":"83","author":"Verma","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.01.005_bib9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12913-014-0614-1","article-title":"Health literacy: health professionals\u2019 understandings and their perceptions of barriers that indigenous patients encounter","volume":"14","author":"Lambert","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clml.2018.01.005_bib10","first-page":"51","article-title":"Low health literacy: a barrier to effective patient care","volume":"66","author":"Seurer","year":"2013","journal-title":"South Dakota Med"},{"key":"10.1016\/j.clml.2018.01.005_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.puhe.2015.04.001","article-title":"Exposing some important barriers to health care access in the rural USA","volume":"129","author":"Douthit","year":"2015","journal-title":"Pub Health"},{"key":"10.1016\/j.clml.2018.01.005_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2014.04.011","article-title":"Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee","volume":"14","author":"Raje","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.01.005_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.01.005_bib14","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib15","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/1078-0432.CCR-12-1881","article-title":"New strategies in the treatment of multiple myeloma","volume":"19","author":"Munshi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.01.005_bib16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.01.005_bib17","doi-asserted-by":"crossref","unstructured":"Fiala MA, Dukeman J, Tuchman SA, Keller M, Vij R, Wildes TM. Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets [e-pub ahead of print]. JCO Clin Cancer Inform https:\/\/doi.org\/10.1200\/CCI.17.00089, accessed February 2, 2018.","DOI":"10.1200\/CCI.17.00089"},{"key":"10.1016\/j.clml.2018.01.005_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chron Dis"},{"key":"10.1016\/j.clml.2018.01.005_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2018.01.005_bib20","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.005_bib21","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma. American Society of Clinical Oncology meeting","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2018.01.005_bib22","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.01.005_bib23","first-page":"261","article-title":"Geriatric assessment for oncologists","volume":"12","author":"Korc-Grodzicki","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clml.2018.01.005_bib24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib25","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study","volume":"34","author":"Corre","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib26","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2013.55.0418","article-title":"Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations","volume":"32","author":"Hurria","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib27","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.005_bib28","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.01.005_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib30","doi-asserted-by":"crossref","first-page":"dju067","DOI":"10.1093\/jnci\/dju067","article-title":"Multiple myeloma in the very old: an IASIA conference report","volume":"106","author":"Tuchman","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2018.01.005_bib31","series-title":"Race is associated with bortezomib but not lenalidomide utilization during first-line treatment of multiple myeloma","author":"Fiala","year":"2017"},{"key":"10.1016\/j.clml.2018.01.005_bib32","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma","volume":"35","author":"Olszewski","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.01.005_bib33","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma, version 2.2016: clinical practice guidelines in oncology","volume":"13","author":"Anderson","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2018.01.005_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.clml.2018.01.005_bib35","series-title":"Hospice use among patients with myeloma","author":"Odejide","year":"2017"},{"key":"10.1016\/j.clml.2018.01.005_bib36","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnci\/dji189","article-title":"Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants","volume":"97","author":"Lamont","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2018.01.005_bib37","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1097\/MLR.0b013e31823ab60f","article-title":"Identifying specific chemotherapeutic agents in Medicare data: a validation study","volume":"51","author":"Lund","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2018.01.005_bib38","doi-asserted-by":"crossref","first-page":"A746","DOI":"10.1016\/j.jval.2016.09.2283","article-title":"Eliciting individual patient preferences on the benefits and risks of cancer treatments: results from a survey conducted in myeloma patients","volume":"19","author":"Postmus","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2018.01.005_bib39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017314933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:14Z","timestamp":1761870614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017314933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2152265017314933"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.01.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}